
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
15 June 2018
MP opens Leukaemia UK Ambulatory Care Unit
A unit funded by Leukaemia UK which allows people with blood cancer to have stem cell transplants as out-patients has been officially opened by its first patient, Nick Boles MP
9 May 2018
Sharing this exciting news: a treatment advance for childhood leukaemia
A deal has been struck to let the NHS offer children an expensive new cancer therapy that has been called the most exciting treatment advance for decades
28 November 2022
Leukaemia UK John Goldman Fellow awarded Professorship
Talented blood cancer researcher, Vignir Helgason, was awarded a Leukaemia UK John Goldman Fellowship in 2015, for his research into chronic myeloid leukaemia (CML). Since then, his research career has…
18 July 2021
Open letter from cancer charities to the public
40 charities and organisations have written an open letter, urging the public to help keep vulnerable people safe as restrictions ease.